SITC 2022: Preclinical data for SNS-102
Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4.
Expanding the range of immunotherapy options has been challenging for a number of reasons, including on-target/off-tumor activity, an immunosuppressive tumor microenvironment, and the cost and time constraints of personalized treatment.
Disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors